DELFI Diagnostics Presents Additional Promising Proof-of-Concept Data on its Monitoring Program at AACR 2023
The data were presented at the American Association for Cancer Research (AACR) 2023 Annual Meeting and builds on earlier studies showing the potential of using DELFI's technology for treatment monitoring.
- The data were presented at the American Association for Cancer Research (AACR) 2023 Annual Meeting and builds on earlier studies showing the potential of using DELFI's technology for treatment monitoring.
- The study builds on prior work demonstrating the potential of the DELFI platform to monitor patients with metastatic cancer undergoing treatment with immunotherapy.
- Also at AACR, DELFI and other researchers using the DELFI platform presented data describing the platform's strong performance in a training set that will be used to develop DELFI's first lung cancer screening product.
- Researchers also shared promising initial data on the DELFI platform's ability to detect early stage ovarian cancer.